Rare Diseases Working Group Should Address CLIA Lab Participation – SACGT
This article was originally published in The Gray Sheet
Executive Summary
The Rare Diseases Working Group of the HHS Secretary's Advisory Committee on Genetic Testing should look at ways to shift testing for rare diseases from research labs to CLIA-certified clinical labs, the committee concluded
You may also be interested in...
DePuy Weighs HDE Costs; FDA Stresses Data Options Over Statutory Limits
The Center for Devices & Radiological Health is encouraging greater use of humanitarian device exemptions by inviting manufacturers to submit alternative forms of data to support submissions
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.